Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies

Although intravenous (i.v.) bisphosphonates are the standard of care for metastatic bone disease, they are less than ideal for many patients due to infusion-related adverse events (AEs), an increased risk of renal toxicity and the inconvenience of regular hospital visits. The use of oral bisphosphon...

Descripción completa

Detalles Bibliográficos
Autores principales: Body, J J, Diel, I J, Lichinitzer, M, Lazarev, A, Pecherstorfer, M, Bell, R, Tripathy, D, Bergstrom, B
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409647/
https://www.ncbi.nlm.nih.gov/pubmed/15026791
http://dx.doi.org/10.1038/sj.bjc.6601663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409647/
https://www.ncbi.nlm.nih.gov/pubmed/15026791
http://dx.doi.org/10.1038/sj.bjc.6601663

Ejemplares similares